Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupHead and Neck OncologyradiotherapyDiseaseHead and Neck Tumors (Squamous Cell)Nasopharyngeal CarcinomaSubgroupHPV positivePD-L1 with CPS from 1ICD10C11.-C11.8C11.9C76.0MeSHHypopharyngeal NeoplasmsLaryngeal NeoplasmsMouth NeoplasmsOropharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckSequenceCETU(400/250)/CISP100, Head and Neck Tumors, C1 (PID1246) -|- CETU250/CISP100, C2+ (PID1271)CETU(400/250)/DOCE75/CISP100/FU700, Head and Neck Tumors, C1 (PID1348) -|- CETU250/CISP100/DOCE75/FU700, C2-3 (PID1349)CETU(400/250)/PACL175/CISP75, Head and Neck Tumors, C1 (PID1273) -|- CETU250/PACL175/CISP75, C2+ (PID1274)CETU400, Head and Neck Tumors, C1 (PID1220) -|- CETU250, C2+ (PID1221)CETU400/CRBP5/FU1000, Head and Neck Tumors, C1 (PID623) -|- CETU250/CRBP5/FU1000, C2+ (PID337)CETU400/PACL40/CRBP2/Radiation, Head and Neck Tumors, C1 (PID622) -|- CETU250/PACL40/CRBP2/Radiation, Head and Neck Tumors, C2+ (PID621)CETU400/PACL80, Head and Neck Tumors, C1 (PID707) -|- CETU250/PACL80, C2+ (PID708)CETU400/PACL90/CRBP2, Head and Neck Tumors, C1 (PID1242) -|- C2-6 (PID1243) -|- C7-11 (PID1244)CETU400/Radiation, Head and Neck Tumors, C1 (PID1194) -|- CETU250/Radiation, C2+ (PID1195)CISP12/FU600/Radiation, Head and Neck Tumors, C1-2 (PID2059) -|- C3 (PID2060) -|- C4 (PID2062)CISP100/Radiatio, Head and Neck Tumors (PID1334) -|- CISP100/CAPE1000, Nasopharyngeal Ca (PID1784).DOCE60/CISP60/FU600, Nasopharyngeal Ca (PID1373) -|- CISP100/Radiation, Head and Neck Tumors (PID1334)DOCE75/CISP75/FU750, Head and Neck Tumors (PID1102) -|- CRBP1.5/Radiation (PID1282)GEMC1000/CISP80, Nasopharyngeal Ca (PID1325) -|- CISP100/Radiation (PID1334)GORTEC: TPEx (CETU(400/250)/DOCE75/CISP75), Head and Neck Tumors, C1 (PID1275) -|- TPEx (CETU250/DOCE75/CISP75), C2+ (PID1276)KEYNOTE-048: PEMB200/CISP100/FU1000, Head and Neck Tumors, First Line (PID1447) -|- PEMB200 (PID1445)KEYNOTE-048: PEMB200/CRBP5/FU1000, Head and Neck Tumors, first-line (PID1446) -|- PEMB200 (PID1445)KEYNOTE-689: PEMB200, Head and Neck Tumors, neoadj., C1-2 (PID2970) -|- PEMB200/CISP100/Radiation, adj., C3-5 (PID2971) -|- PEMB200, C6-17 (PID2972)ChemotherapyChemo-substanceCarboplatinCetuximabCisplatinDocetaxelEnfortumab VedotinFluorouracilMethotrexateMitomycinNivolumabPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelEnfortumab VedotinFluorouracilMethotrexateMitomycinNivolumabPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelEnfortumab VedotinFluorouracilMethotrexateMitomycinNivolumabPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelEnfortumab VedotinFluorouracilMethotrexateMitomycinNivolumabPaclitaxelPembrolizumabNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideNo. Substances12345678101112Protocol classificationTherapy classificationalternativecurrent standardIntensityLow doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseInductionneoadjuvantPre-phaseTherapy intentioncurativepalliativeRisksAllergic ReactionAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaCardiotoxicityConstipationDehydrationDiarrheaDysphagiaDyspneaEmetogenicity (MASCC/ESMO)EsophagitisExanthema, AcneiformFatigueFebrile NeutropeniaGastrointestinal ToxicityHeadacheHepatotoxicityHypertensionHyperthyroidismHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaHypothyroidismIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisNail ChangesNephrotoxicityNeuropathyNeurotoxicityNeutropeniaOral MucositisOtotoxicityPainPneumoniaPneumonitisPruritusPyrexiaRadiation DermatitisRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAdelstein DBauml JBauml J / Cohen E Bonner JBonner JBossi PBrizel DMBudach V Burtness BCalais GCooper JFerris RFury MGhi MGrau JGuardiola EGuigay JHaddad RHitt RMaring SMedina JAMehanna HNoronha VPatil VMPosch DPosner MSamlowski ESuntharalingam MSwiecicki PLTao Y Uppaluri RVermorken JVermorken JBWanebo HDiseasefortgeschrittener Kopf-Hals-Tumor, Erstlinie, Stadium III-IV, ECOG 0-1fortgeschrittenes Oropharynxkarzinom, nicht metastasiert, Stadium III-IV, Karnofsky <60Karzinom des Oro- und, Hypopharynx, Larynx, Stadium III und IV, nicht metastasiert, Erstlinie, Karnofsky > 60Kopf-Hals-Tumor,nicht-metastasiert, cisplatinungeeignet, ECOG 0-1Kopf-Hals-Tumor, Stadium III-IVA, ECOG 0-1Kopf-Hals-Tumoren (Plattenepithel-), adjuvant, ECOG 0-1Kopf-Hals-Tumoren (Plattenepithel-), resektabel, Stadium III-IV, ECOG 0-1Kopf-Hals-Tumoren, cTx cNx cM0, nicht cisplatingeeignet, ECOG 0-2Kopf-Hals-Tumoren, nicht resektabel, UICC Stadium III/IV, ECOG 0-1Kopf-Hals-Tumoren, Plattenepithel-, Erstlinie, ECOG 0-1Kopf-Hals-Tumoren, Plattenepithel-Ca, cT3/cT4, cN0-3, cM0 (bei Zungengrund-Ca max. cT2cN0), 18-75J., ECOG 0-2Kopf-Hals-Tumoren, Stadium III -IV, nicht metastasiert, Erstlinie, ECOG 0-1Kopf-Hals-Tumoren, Stadium III oder IV, ohne Fernmetastasen, Erstlinientherapie, ECOG 0-2Kopf-Hals-Tumoren, Stadium IV, platinresistent, Rezidivtherapie, ECOG: 0-2local rezidivierte oder metastasierte Kopf-Hals-Tumoren, Erstlinie, ECOG 0-2Lokal fortgeschrittene Kopf-Hals-Tumoren, Stadium III und IV, adjuvant oder definitive Chemo-Radiotherapie ECOG 0-2Lokal fortgeschrittener oder metastasierter Kopf-Hals-Tumor nach platinhaltiger Therapie und Therapie mit Anti-PD-1/L1-Inhibitoren, ECOG 0-1lokal fortgeschrittenes, nicht reserzierbares Plattenepithel-Karzinom des Kopf/Halses, Stadium III-IV,M0 Erstlinie, Karnofsky >70Lokal fortgeschrittenes, nicht resezierbares Plattenepithelzellkarzinom des Kopf-Hals-Bereichsmetastasierter oder rezidivierter Kopf-Hals-Tumor, Stadium III-IV, nach Cisplatin, Karnofsky > 60Neudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1neudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1Nicht resezierbare Kopf-Hals-Tumoren (Plattenepithel-), Stadium III - IV, ECOG 0-1Oropharynxkarzinom (Plattenepithel), HPV-positiv und low-risk (nie Raucher oder weniger als 10 PY), T3N0–T4N0, and T1N1–T4N3, ECOG 0-1rezidivierende oder metastasierte Kopf-Hals-Tumoren, Zweitlinie, ECOG 0-2Rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), ECOG 0-1Rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), Erstlinie, ECOG 0-1rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), Erstlinie, ECOG 0-1Rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), Erstlinie, ECOG 0-1Rrezidivierte oder metastasierte Kopf-Hals-Tumoren, Erstlinie, ECOG 0-2rezidivierter oder metastasierter Kopf-Hals-Tumor, Erstlinie, ECOG 0-1rezidiviertes/metastasiertes, platin- und cetuximabrefraktäres Plattenepithelzellkarzinom des Kopf-Hals-Bereichs, ECOG 0-2 rezidiviertes oder metastasiertes Plattenepithelkarzinom des Larynx oder Pharynx, Karnofsky > 70wiederkehrender oder metastasierter Kopf-Hals-Tumor nach PlatintherapieWiederkehrendes oder metastasiertes Plattenepithel-Karzinom des Kopf und Halses, Karnofsky >70, ErstlinieWiederkehrendes oder metastasiertes Plattenepithelkarzinom des Larynx oder Pharynx, Karnofsky > 70OriginAntwerp University Hospital, Department of Medical Oncology, Edegem, BelgiumBrigham and Women's Hospital, Harvard Medical School, Boston, KEYNOTE-689 trialCentre Hospitalier Universitaire Tours, France, 94-01 French Head and Neck Oncology and Radiotherapy GroupCHU Jean Minjoz, Service Oncologie medicale, Cedex, FranceCleveland Clinic Foundation, ClevelandDana–Farber Cancer Institute, Boston, TAX 324 Study GroupDepartment of Internal Medicine, Yale University School of Medicine, Eastern Cooperative Oncology Group Study Department of Medical Oncology, Centre Antoine Lacassagne, Nice, TPEx, GORTEC studyDepartment of Medical Oncology, Dana Farber Cancer Institute, BostonDepartment of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, IndiaDepartment of Medical Oncology, University Hospital Antwerp, Edegem, BelgiumDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New YorkDepartment of Medicine, University of Alabama, BirminghamDepartment of Radiation Oncology, University Hospital of Muenster, Muenster, GermanyDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore BDDepartment of Surgery, Landmark Medical Center, Woonsocket, ECOG-ACRIN trial (E2303)Deptartment of Internal Medicine I und CCC, Medical University of ViennaDuke Comprehensive Cancer Center, Duke University Medical Center, Durham, USAGORTEC 2015-01 PembroRadHead and Neck Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, MilanHead and Neck Oncology, Dana Farber Cancer Institute, arvard Medical School, Boston, MassachusettsInstitute for Head and Neck Studies and Education (InHANSE), University of Birmingham, UK, De-ESCALaTE HPV trialMedical Oncology Department, Ospedale dell’Angelo, Venezia, the GSTTC Italian Study GroupNew York University Medical Center, New York, Radiation Therapy Oncology Group 9501/IntergroupOhio State University Comprehensive Cancer Center, Ohio State University, ColumbusOncology Department, Institut Clinic de Malalties Hemato-Oncologiques, University of BarcelonaServicio de Oncologia Radioterapica, Hospital Clinico Universitario, Malaga, SpainSpanish Head and Neck Cancer Cooperative Group, TTCCTata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, IndiaUniversitair Ziekenhuis Antwerpen, Edegem, BelgiumUniversity Hospitals Charite, Berlin, German Cancer Society 95-06 trialUniversity of Michigan Rogel Cancer Center, Ann Arbor, USAUniversity of Pennsylvenia, PhiladelphiaUniversity of Pennsylvenia, Philadelphia, Keynote-040University of Utah Health Science Center, Salt Lake City, Utah, A Southwest Oncology GroupYale School of Medicine and Yale Cancer Center, New Haven, CT, USA, Keynote-048Protocols in Revision 54 protocols foundCarboplatin 1.5 / Radiation, Head and Neck Tumors (PID1282 V1.0)Carboplatin 70 / Fluorouracil 600 / Radiation, Oropharyngeal Carcinoma (PID1708 V1.1)Cetuximab (400/250) / Cisplatin 100, Head and Neck Tumors, Cycle 1 (PID1246 V1.2)Cetuximab (400/250) / Docetaxel 75 / Cisplatin 100 / Fluorouracil 700, Head and Neck Tumors, Cycle 1 (PID1348 V1.3)Cetuximab (400/250) / Docetaxel 75 / Cisplatin 75, Head and Neck Tumors, Cycle 1 (PID1275 V1.2)Cetuximab (400/250) / Paclitaxel 175 / Cisplatin 75, Head and Neck Tumors, Cycle 1 (PID1273 V1.2)Cetuximab 250 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, C2+ (PID337 V2.1)Cetuximab 250 / Cisplatin 100 / Docetaxel 75 / Fluorouracil 700, Head and Neck Tumors, Cycle 2-3 (PID1349 V1.3)Cetuximab 250 / Cisplatin 100, Head and Neck Tumors, Cycle 2+ (PID1271 V1.2)Cetuximab 250 / Docetaxel 75 / Cisplatin 75, Head and Neck Tumors, Cycle 2+ (PID1276 V1.2)Cetuximab 250 / Paclitaxel 175 / Cisplatin 75, Head and Neck Tumors, Cycle 2+ (PID1274 V1.2)Cetuximab 250 / Paclitaxel 30 / Carboplatin 1 / Radiation, Head and Neck Tumors, Cycle 7-11 (PID1244 V1.1)Cetuximab 250 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 2+ (PID621 V1.1)Cetuximab 250 / Paclitaxel 80, Head and Neck Tumors, Cycle 2+ (PID708 V1.1)Cetuximab 250 / Paclitaxel 90 / Carboplatin 2, Head and Neck Tumors, Cycle 2-6 (PID1243 V1.1)Cetuximab 250 / Radiation, Head and Neck Tumors, Cycle 2+ (PID1195 V1.1)Cetuximab 250, Head and Neck Tumors, Cycle 2+ (PID1221 V1.2)Cetuximab 400 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, C1 (PID623 V2.1)Cetuximab 400 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 1 (PID622 V1.1)Cetuximab 400 / Paclitaxel 80, Head and Neck Tumors, Cycle 1 (PID707 V1.1)Cetuximab 400 / Paclitaxel 90 / Carboplatin 2, Head and Neck Tumors, Cycle 1 (PID1242 V1.1)Cetuximab 400 / Radiation, Head and Neck Tumors, Cycle 1 (PID1194 V1.1)Cetuximab 400, Head and Neck Tumors, Cycle 1 (PID1220 V1.2)Cetuximab 500 / Docetaxel 50, Head and Neck Tumors (PID1277 V1.1)Cetuximab 500, Head and Neck Tumors (PID1241 V1.1)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1334 V1.1)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1640 V1.1)Cisplatin 100 / Radiation, Head and Neck Tumors, adjuvant (PID1291 V1.1)Cisplatin 100, Head and Neck Tumors (PID1245 V1.1)Cisplatin 12 / Fluorouracil 600 / Radiation, Head and Neck Tumors, cycle 1-2 (PID2059 V1.0)Cisplatin 16 / fluorouracil 600, Head and Neck Tumors, cycle 3 (PID2060 V1.0)Cisplatin 20 / Fluorouracil 600, Head and Neck Tumors, cycle 4 (PID2062 V1.0)Cisplatin 20 / Fluorouracil 800 / Radiation, Head and Neck Tumors (PID2066 V1.0)Cisplatin 30 / Radiation, Head and Neck Tumors, adjuvant (PID1240 V1.1)Cisplatin 40 / Radiation, Head and Neck Tumors (PID1637 V1.1)Docetaxel 15 / Radiatio, Head and Neck Tumors (PID2259 V1.0)Docetaxel 65 / Carboplatin 6, Head and Neck Tumors (PID1278 V1.0)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750, Head and Neck Tumors (PID1102 V1.1)Enfortumab Vedotin 1.25, Head and Neck Tumors (PID2857 V1.0)Fluorouracil 600 / Mitomycin 10 / Radiation, Head and Neck Tumors (PID2058 V1.0)Methotrexate 40, Head and Neck Tumors (PID1281 V1.0)Nivolumab 240, Head and Neck Tumors (PID856 V2.0)Paclitaxel 40 / Carboplatin 1 / Radiation, Head and Neck Tumors (PID2386 V1.0)Paclitaxel 45 / Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1295 V1.1)Paclitaxel 80, Head and Neck Tumors (PID1216 V1.1)Pembrolizumab 200 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, first-line (PID1446 V1.1)Pembrolizumab 200 / Cisplatin 100 / Fluorouracil 1000, Head and Neck Tumors (PID1447 V1.1)Pembrolizumab 200 / Cisplatin 100 / Radiation, Head and Neck Tumors, adjuvant, cycle 3-5 (PID2971 V1.0)Pembrolizumab 200 / Radiation, Head and Neck Tumors (PID2258 V1.0)Pembrolizumab 200, Head and Neck Tumors, adjuvant, cycle 6-17 (PID2972 V1.0)Pembrolizumab 200, Head and Neck Tumors, first-line (PID1445 V1.0)Pembrolizumab 200, Head and Neck Tumors, neoadjuvant, cycle 1-2 (PID2970 V1.0)Pembrolizumab 200, Head and Neck Tumors, Second Line (PID239 V1.0)Pembrolizumab 400, Head and Neck Tumors (PID1270 V1.0)
